You are here: Industry Insights > Clover Biopharmaceuticals

News List

Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine prnewswire
September 13, 2021
Clover Biopharmaceuticals, Ltd. (Clover), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that its wholly-owned subsidiary...
COVID-19 S-Trimer vaccine candidates show promise in early trials europeanpharmaceuticalreview
December 08, 2020
When adjuvanted with GSK’s pandemic adjuvant system, the S-Trimer vaccine candidates induced the production of neutralising antibodies in all trial participants.
Cytiva supports Clover Biopharmaceuticals to scale up the output of its vaccine candidate prnasia
November 16, 2020
Cytiva, a global life sciences leader, is supporting Clover Biopharmaceuticals, a global clinical-stage biotechnology company, to help accelerate the development and manufacturing of a protein-based S-Trimer subunit vaccine candidate.
CEPI to fund Clover’s Covid-19 vaccine development pharmaceutical-technology
November 06, 2020
The Coalition for Epidemic Preparedness Innovations (CEPI) has extended its partnership to fund the development of Sichuan Clover Biopharmaceuticals’ protein-based S-Trimer Covid-19 vaccine candidate.
CEPI Expands Partnership with Clover contractpharma
July 14, 2020
To rapidly advance development and manufacture of COVID-19 vax candidate, invests an additional $66M upfront in Clover’s S-Trimer protein.
CEPI expands Covid-19 vaccine alliance with Clover Biopharmaceuticals pharmaceutical-technology
July 09, 2020
The Coalition for Epidemic Preparedness Innovations (CEPI) has expanded its collaboration with China-based Sichuan Clover Biopharmaceuticals to speed-up the development and manufacture of Covid-19 vaccine candidate.
CEPI Inks COVID-19 Vax Pact with Clover Bio contractpharma
May 05, 2020
Becomes ninth global COVID-19 vaccine development project that CEPI has signed since Jan 23, 2020.
Clover Biopharmaceuticals gets CEPI funding for Covid-19 vaccine harmaceutical-technology
April 30, 2020
The Coalition for Epidemic Preparedness Innovations (CEPI) has signed an agreement with Clover Biopharmaceuticals Australia, a subsidiary of China-based Sichuan Clover Biopharmaceuticals, to support the development of a Covid-19 vaccine candidate.
Tianhe Life Sciences leads $9.5m Series A in Clover Biopharma biospectrumasia
December 19, 2017
Tianhe Life Sciences leads $9.5m Series A in Clover Biopharma Clover is utilising its proprietary Trimer-Tag technology platform to develop biologics targeting trimerization-dependent pathways.